Kenyon, C., Chang, J., Gensch, E., Rudner, A
This growth is driven by an increased demand for weight-loss agents and the need to control the global obesity epidemic. The market is currently dominated by Novo Nordisk and Eli Lilly and their respective glucagon-like peptide-1 (GLP-1) agonists, semaglutide and tirzepatide
Women of childbearing potential should discuss contraception, as tirzepatide can decrease exposure to oral contraceptives, requiring backup contraception for 4 weeks after initiation and after each dose increase
I appreciate beauty in any form
If you are a coach who wants to, or is working with patients prescribed GLP-1s, then watch for the upcoming Wellcoaches course offering on Obesity and GLP-1 use